Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Clinical Pharmacology and Toxicology of Cannabis-Based Medicinal Products"
A special issue of Psychoactives (ISSN 2813-1851).
Deadline for manuscript submissions: 31 December 2023 | Viewed by 1134
Special Issue Editors
Interests: toxicology; drugs of abuse; amphetamines; synthetic cathinones; psychoactive substances; toxicometabolomics; cancer metabolomics; biomarkers; hepatotoxicity; nephrotoxicity; cardiotoxicity; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Special Issue in Metabolites: Toxicometabolomics
Special Issue in International Journal of Molecular Sciences: Chronic Kidney Disease: Underlying Molecular Mechanisms
Interests: pharmacology; substance use disorders; psychiatric disorders; cannabis; cannabinoid receptor; genetic polymorphisms; catechol-O-methyltransferase; depression
Special Issue Information
In light of recent policy changes, cannabis and its derivatives can now be prescribed for medicinal use in many countries. This has created new therapeutic opportunities for the treatment of a variety of diseases and clinical symptoms such as chronic pain, spasticity in multiple sclerosis, seizures in refractory epilepsy, intractable nausea and/or vomiting, depression and anxiety, to name a few. A wide range of cannabis-based products, including dried flowers, standardized plant extracts, THC- or CBD-only products, and pure synthetic cannabinoids are available for therapeutic purposes. However, medicinal cannabis may also pose health risks associated with its use, such as psychoactive, intoxicating, and impairing effects. Therefore, high-quality evidence of its safety and efficacy must be provided before cannabis and its derivatives can be used to their full potential as future medicines.
The aim of this Special Issue is to publish novel research contributing to the development of knowledge on the potential uses and side effects associated with medical cannabis and its derivatives. As such, we encourage submissions addressing, but not limited to, pharmacologic mechanisms, therapeutic uses, clinical trials, medical and psychiatric adverse effects, pharmacovigilance, and drug interactions. Original research and review papers are welcomed.
We look forward to receiving your work.
Prof. Dr. Márcia Carvalho
Prof. Dr. Maria Augusta Vieira-Coelho
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Psychoactives is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- medicinal cannabis
- endocannabinoid system
- adverse effect
- drug interactions